BlackRock Discloses Passive Stake in Oric Pharmaceuticals
Ticker: ORIC · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1796280
| Field | Detail |
|---|---|
| Company | Oric Pharmaceuticals, Inc. (ORIC) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a passive stake in Oric Pharma, signaling institutional confidence.**
AI Summary
BlackRock, Inc. reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Oric Pharmaceuticals, Inc. (NASDAQ: ORIC). This filing, an SC 13G, indicates that BlackRock is a passive investor, meaning they don't intend to influence Oric's management or business decisions. For investors, this signals that a major institutional player sees value in Oric, potentially adding a layer of stability and confidence, but it doesn't suggest any immediate strategic changes for the company.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant, passive stake in Oric Pharmaceuticals, which can be seen as a vote of confidence in the company's long-term prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of a passive investment by a large institution, which generally reduces rather than increases risk for existing shareholders.
Analyst Insight
A smart investor would view this as a positive sign of institutional confidence, but recognize it doesn't signal any imminent strategic changes or activist involvement from BlackRock. It's a data point for long-term conviction rather than a short-term trading signal.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Oric Pharmaceuticals, Inc. (company) — the subject company in which BlackRock holds a stake
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain its passive investment in Oric Pharmaceuticals for the foreseeable future. (BlackRock, Inc.) — high confidence, target: 2025-01-29
- Oric Pharmaceuticals' stock price will experience minor, if any, immediate impact from this passive disclosure. (Oric Pharmaceuticals, Inc.) — medium confidence, target: 2024-02-05
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G filing, which is used by institutional investors like BlackRock to report a passive ownership stake of 5% or more in a company's stock. It indicates that the investor does not intend to influence or change the control of the company.
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742 and located at 50 Hudson Yards, New York, NY.
Which company's securities are the subject of this filing?
The subject company is Oric Pharmaceuticals, Inc., identified by CIK 0001796280, with its business address at 240 E. Grand Ave., 2nd Floor, South San Francisco, CA.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding Oric Pharmaceuticals, Inc. (ORIC).